陈美宁,丁寿亮,李永宝,等.ArcherQA系统在磁共振引导在线自适应放疗计划独立验算中的应用研究[J].中华放射医学与防护杂志,2024,44(5):379-385.Chen Meining,Ding Shouliang,Li Yongbao,et al.Application of ArcherQA for independent dose verification of MR-guided online adaptive radiotherapy plans[J].Chin J Radiol Med Prot,2024,44(5):379-385
ArcherQA系统在磁共振引导在线自适应放疗计划独立验算中的应用研究
Application of ArcherQA for independent dose verification of MR-guided online adaptive radiotherapy plans
投稿时间:2023-07-24  
DOI:10.3760/cma.j.cn112271-20230724-00018
中文关键词:  磁共振引导放疗  在线自适应放疗  独立验算  ArcherQA
英文关键词:Magnetic resonance guided radiotherapy  Online adaptive radiotherapy  Independent dose verification  ArcherQA
基金项目:国家重点研发计划项目(2022YFC2404604);广州市基础与应用基础研究项目(202201011090);广东省基础与应用基础研究基金项目(2021A1515110642);国家自然科学基金项目(12275372);广东省自然科学基金(2023A1515011153);中华国际医学交流基金会肿瘤精准放疗星火计划(2019-N-11-34)
作者单位E-mail
陈美宁 中山大学肿瘤防治中心放疗科 华南肿瘤学国家重点实验室 肿瘤医学协同创新中心 广东省恶性肿瘤临床医学中心, 广州 510060  
丁寿亮 中山大学肿瘤防治中心放疗科 华南肿瘤学国家重点实验室 肿瘤医学协同创新中心 广东省恶性肿瘤临床医学中心, 广州 510060  
李永宝 中山大学肿瘤防治中心放疗科 华南肿瘤学国家重点实验室 肿瘤医学协同创新中心 广东省恶性肿瘤临床医学中心, 广州 510060  
王彬 中山大学肿瘤防治中心放疗科 华南肿瘤学国家重点实验室 肿瘤医学协同创新中心 广东省恶性肿瘤临床医学中心, 广州 510060  
程博 中国科学技术大学核医学物理研究所, 合肥 210027  
裴曦 中国科学技术大学核医学物理研究所, 合肥 210027  
黄晓延 中山大学肿瘤防治中心放疗科 华南肿瘤学国家重点实验室 肿瘤医学协同创新中心 广东省恶性肿瘤临床医学中心, 广州 510060  
刘红冬 中山大学肿瘤防治中心放疗科 华南肿瘤学国家重点实验室 肿瘤医学协同创新中心 广东省恶性肿瘤临床医学中心, 广州 510060 liuhd@sysucc.org.cn 
摘要点击次数: 964
全文下载次数: 392
中文摘要:
      目的 探究将ArcherQA系统用于Elekta Unity 1.5T磁共振加速器上开展的磁共振引导自适应放疗计划独立验算的可行性。方法 利用均匀水模体验证了ArcherQA在磁场下的剂量计算精度,然后利用抽签法随机选取32例在Unity上接受磁共振引导在线自适应放疗的患者,包含脑、纵隔、肝、肾、椎体等5个治疗部位、32个离线计划,177个在线计划。分别比较ArcherQA独立验算结果与ArcCheck测量结果、Monaco计划系统计算结果的γ通过率(3 mm/3%、2 mm/2%,阈值10%),定量评估ArcherQA系统对Unity在线计划独立验算的准确性和效率。结果 ArcherQA系统可以较为准确地计算出磁场下光子线的剂量分布,在3 mm/3%标准下,水模体中方野验证结果γ通过率均高于99%。在更严格的2 mm/2%标准下,除20 cm × 20 cm射野外,其他方野的γ通过率也都超过95%。对于治疗计划验证,ArcherQA计算的结果与ArcCheck测量数据,以及Monaco计划系统的计算数据都表现出较好的一致性,在3 mm/3%标准下平均γ通过率可达到99%以上,2 mm/2%标准下平均γ通过率也超过97%。ArcherQA的在线计划独立验算效率较高,177个在线计划独立验算所需的时长范围为50~150 s,平均时长约为108 s。结论 ArcherQA可以准确并高效地计算出磁场下光子线的剂量分布,能够用于磁共振引导自适应放疗中离线和在线治疗计划的独立验算,是一种有效的补充验证手段,为患者治疗计划安全提供保障。
英文摘要:
      Objective To explore the feasibility of applying ArcherQA to independent dose verification of MR-guided online adaptive radiotherapy (ART) plans performed on Elekta Unity 1.5 Tesla (T) magnetic resonance-linear accelerator (MR-Linac). Methods The dose calculation accuracy of ArcherQA under a specific magnetic field was validated using a homogeneous water phantom. A total of 32 patients who received MR-guided online ART on Elekta Unity were randomly selected by lottery, with 32 offline plans and 177 online plans for five treatment sites (brain, mediastinum, liver, kidney, and vertebral body) enrolled. Finally, the γ pass rates (threshold: 10%; criteria: 3 mm/3% and 2 mm/2%) were compared among the result upon independent dose verification of ArcherQA, measurements of ArcCheck, and calculations using the Monaco treatment planning system (TPS) to quantitatively evaluate the accuracy and efficiency of ArcherQA in independent dose verification of online plans on Elekta Unity. Results ArcherQA was proven accurate in calculating the dose distribution of therapeutic photon beams under the specific magnetic field. With the 3 mm/3% criterion, the γ pass rates of verification result exceeded 99% in all square fields of a water phantom. Under the stricter 2 mm/2% criterion, the γ pass rates also surpassed 95% in all square fields except 20 cm × 20 cm field. Regarding the verification of treatment plans, the ArcherQA result were found to be highly consistent with those measured or calculated using ArcCheck and Monaco TPS, with the average γ pass rates exceeding 99% under the 3 mm/3% criterion and above 97% under the 2 mm/2% criterion. ArcherQA was acceptably efficient for independent dose verification of online plans, with 50 to 150 s, (108 s on average) required to complete the independent dose verification of 177 online plans. Conclusions ArcherQA allows for accurately and efficiently calculating the dose distribution of therapeutic photon beams under a specific magnetic field, establishing it as an effective supplementary tool for independent dose calculation of MR-guided offline and online ART plans, thereby ensuring the safety of patient treatment plans.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭